MedTrace Logo

Cabozantinib in Men With Castration-Resistant Prostate Cancer

NCT01703065 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-12-04

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Adenocarcinoma of the Prostate
  • Castration-resistant Prostate Cancer
  • Recurrent Prostate Cancer
  • Stage III Prostate Cancer
  • Stage IV Prostate Cancer

Interventions

DRUG

Cabozantinib

Given orally once a day

Sponsors & Collaborators

  • Prostate Cancer Foundation

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Washington

    lead OTHER

Principal Investigators

  • Celestia S Higano, MD · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-18
Primary Completion
2015-02-02
Completion
2015-09-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01703065 on ClinicalTrials.gov